Global PD-1/PD-L1 Checkpoint Inhibitors Market
授權報價
| Single User License | $3,480 USD |
| Multi User License | $5,220 USD |
| Corporate Users License | $6,960 USD |
完整報告名稱與涵蓋範圍
Global PD-1/PD-L1 Checkpoint Inhibitors Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
報告摘要
According to our (Global Info Research) latest study, the global PD-1/PD-L1 Checkpoint Inhibitors market size was valued at US$ 59840 million in 2025 and is forecast to a readjusted size of US$ 122780 million by 2032 with a CAGR of 10.9% during review period.
PD-1/PD-L1 checkpoint inhibitors are a class of immuno-oncology therapies designed to block the immune-suppressive signaling pathway that tumors exploit to deactivate T-cell–mediated antitumor immunity. These agents address the unmet need of patients whose tumors are resistant or poorly responsive to conventional chemotherapy and targeted therapies. The concept emerged as researchers uncovered how malignant cells overexpress PD-L1 or engage PD-1 on T cells to evade immune surveillance; the development of monoclonal antibodies capable of binding and blocking these proteins led to a therapeutic breakthrough, with the first approvals in 2014 reshaping cancer treatment worldwide. Their development and manufacturing rely on an upstream supply chain that includes cell line development materials, recombinant protein expression systems, culture media, buffers, filtration consumables, bioreactors, and aseptic filling components. This also covers nucleic acid materials for antibody engineering, analytical reagents, and instrumentation essential for quality control, forming a comprehensive upstream ecosystem that ensures product consistency, safety, and clinical performance. In 2024, global sales of PD-1/PD-L1 checkpoint inhibitors reached 28.64 million vials, with an average price of USD 1,850 per vial, and corporate gross profit margins ranging between 60% and 70%.
From a market perspective, the PD-1/PD-L1 inhibitor landscape has transitioned from a narrow set of indications to a broad, heterogeneous adoption across cancer types and treatment lines, accompanied by an increasingly crowded supplier ecosystem. Market dynamics are shaped not only by competing products but also by a growing ancillary industry of diagnostic developers, contract manufacturers and service providers that support clinical translation and commercialization. Regional differences in clinical guidelines, payer policies and healthcare infrastructure further lead to heterogeneous uptake patterns, even as overall clinical familiarity and guideline inclusion continue to strengthen usage.
Looking ahead, two complementary trends will dominate: precision immunotherapy and rational combinations. Precision approaches that integrate tumor genomics, immune microenvironment profiling and predictive biomarkers will refine patient selection and improve benefit–risk ratios, while combination regimens aim to broaden responder populations and delay or overcome resistance. Concurrently, platform innovations — such as engineered antibodies, bispecific constructs, long-acting formats and localized delivery systems — will diversify the therapeutic toolbox and open niche application opportunities.
Key growth drivers include persistent unmet clinical needs, robust R&D funding, and evolving regulatory frameworks that increasingly accommodate breakthrough immunotherapies; clinician experience and patient advocacy also accelerate adoption. Major constraints remain: intrinsic and acquired resistance in certain tumor types, uneven access driven by cost and reimbursement variability, and the high technical and capital barriers of biologics development and manufacturing. The interplay among scientific advances, payer decisions and real-world evidence generation will determine how rapidly and equitably these therapies diffuse into broader oncology practice.
This report is a detailed and comprehensive analysis for global PD-1/PD-L1 Checkpoint Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global PD-1/PD-L1 Checkpoint Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PD-1/PD-L1 Checkpoint Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PD-1/PD-L1 Checkpoint Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global PD-1/PD-L1 Checkpoint Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-1/PD-L1 Checkpoint Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-1/PD-L1 Checkpoint Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals, Roche, Pfizer, AstraZeneca, Hengrui Pharmaceuticals, Junshi Biosciences, Innovent, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
PD-1/PD-L1 Checkpoint Inhibitors market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
Market segment by Product Name
Pembrolizumab
Nivolumab
Cemiplimab
Toripalimab
Sintilimab
Tislelizumab
Camrelizumab
Penpulimab
Retifanlimab
Zimberelimab
Atezolizumab
Durvalumab
Avelumab
Envafolimab
Adebrelimab
Market segment by Dosage Strength
100 mg / Vial
200 mg / Vial
240 mg / Vial
300 mg / Vial
Market segment by Application
Squamous Cell Skin Cancer
Non-small Cell Lung Cancer
Melanoma
Gastric Cancer
Other
Major players covered
Bristol Myers Squibb
Merck
Regeneron Pharmaceuticals
Roche
Pfizer
AstraZeneca
Hengrui Pharmaceuticals
Junshi Biosciences
Innovent
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PD-1/PD-L1 Checkpoint Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, with price, sales quantity, revenue, and global market share of PD-1/PD-L1 Checkpoint Inhibitors from 2021 to 2026.
Chapter 3, the PD-1/PD-L1 Checkpoint Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1/PD-L1 Checkpoint Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and PD-1/PD-L1 Checkpoint Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1/PD-L1 Checkpoint Inhibitors.
Chapter 14 and 15, to describe PD-1/PD-L1 Checkpoint Inhibitors sales channel, distributors, customers, research findings and conclusion.
目錄 Table of Contents
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 PD-1 Inhibitors
1.3.3 PD-L1 Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.4.2 Squamous Cell Skin Cancer
1.4.3 Non-small Cell Lung Cancer
1.4.4 Melanoma
1.4.5 Gastric Cancer
1.4.6 Other
1.5 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size & Forecast
1.5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021 & 2025 & 2032)
1.5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (2021-2032)
1.5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price (2021-2032)
2 Manufacturers Profiles
2.1 Bristol Myers Squibb
2.1.1 Bristol Myers Squibb Details
2.1.2 Bristol Myers Squibb Major Business
2.1.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.1.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Bristol Myers Squibb Recent Developments/Updates
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.2.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Merck Recent Developments/Updates
2.3 Regeneron Pharmaceuticals
2.3.1 Regeneron Pharmaceuticals Details
2.3.2 Regeneron Pharmaceuticals Major Business
2.3.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.3.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.4.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Roche Recent Developments/Updates
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.5.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Pfizer Recent Developments/Updates
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.6.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 AstraZeneca Recent Developments/Updates
2.7 Hengrui Pharmaceuticals
2.7.1 Hengrui Pharmaceuticals Details
2.7.2 Hengrui Pharmaceuticals Major Business
2.7.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.7.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Hengrui Pharmaceuticals Recent Developments/Updates
2.8 Junshi Biosciences
2.8.1 Junshi Biosciences Details
2.8.2 Junshi Biosciences Major Business
2.8.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product and Services
2.8.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Junshi Biosciences Recent Developments/Updates
3 Competitive Environment: PD-1/PD-L1 Checkpoint Inhibitors by Manufacturer
3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Manufacturer (2021-2026)
3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Manufacturer (2021-2026)
3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of PD-1/PD-L1 Checkpoint Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 PD-1/PD-L1 Checkpoint Inhibitors Manufacturer Market Share in 2025
3.4.3 Top 6 PD-1/PD-L1 Checkpoint Inhibitors Manufacturer Market Share in 2025
3.5 PD-1/PD-L1 Checkpoint Inhibitors Market: Overall Company Footprint Analysis
3.5.1 PD-1/PD-L1 Checkpoint Inhibitors Market: Region Footprint
3.5.2 PD-1/PD-L1 Checkpoint Inhibitors Market: Company Product Type Footprint
3.5.3 PD-1/PD-L1 Checkpoint Inhibitors Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region
4.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2021-2032)
4.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2032)
4.1.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Region (2021-2032)
4.2 North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
4.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
4.4 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
4.5 South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
4.6 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032)
5 Market Segment by Type
5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type (2021-2032)
5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Type (2021-2032)
6 Market Segment by Application
6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application (2021-2032)
6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Application (2021-2032)
7 North America
7.1 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
7.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
7.3 North America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
7.3.1 North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
7.3.2 North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
8.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
8.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
8.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
8.3.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
8.3.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
9.1 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region
9.3.1 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
10.1 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
10.2 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
10.3 South America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
10.3.1 South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
10.3.2 South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
11.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country
11.3.1 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
12.1 PD-1/PD-L1 Checkpoint Inhibitors Market Drivers
12.2 PD-1/PD-L1 Checkpoint Inhibitors Market Restraints
12.3 PD-1/PD-L1 Checkpoint Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of PD-1/PD-L1 Checkpoint Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of PD-1/PD-L1 Checkpoint Inhibitors
13.3 PD-1/PD-L1 Checkpoint Inhibitors Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PD-1/PD-L1 Checkpoint Inhibitors Typical Distributors
14.3 PD-1/PD-L1 Checkpoint Inhibitors Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 4. Bristol Myers Squibb Major Business
Table 5. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 6. Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 7. Bristol Myers Squibb Recent Developments/Updates
Table 8. Merck Basic Information, Manufacturing Base and Competitors
Table 9. Merck Major Business
Table 10. Merck PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 11. Merck PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 12. Merck Recent Developments/Updates
Table 13. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 14. Regeneron Pharmaceuticals Major Business
Table 15. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 16. Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 17. Regeneron Pharmaceuticals Recent Developments/Updates
Table 18. Roche Basic Information, Manufacturing Base and Competitors
Table 19. Roche Major Business
Table 20. Roche PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 21. Roche PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 22. Roche Recent Developments/Updates
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 26. Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 27. Pfizer Recent Developments/Updates
Table 28. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 29. AstraZeneca Major Business
Table 30. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 31. AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 32. AstraZeneca Recent Developments/Updates
Table 33. Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 34. Hengrui Pharmaceuticals Major Business
Table 35. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 36. Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 37. Hengrui Pharmaceuticals Recent Developments/Updates
Table 38. Junshi Biosciences Basic Information, Manufacturing Base and Competitors
Table 39. Junshi Biosciences Major Business
Table 40. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product and Services
Table 41. Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 42. Junshi Biosciences Recent Developments/Updates
Table 43. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Manufacturer (2021-2026) & (K Units)
Table 44. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Manufacturer (2021-2026) & (USD Million)
Table 45. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 46. Market Position of Manufacturers in PD-1/PD-L1 Checkpoint Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 47. Head Office and PD-1/PD-L1 Checkpoint Inhibitors Production Site of Key Manufacturer
Table 48. PD-1/PD-L1 Checkpoint Inhibitors Market: Company Product Type Footprint
Table 49. PD-1/PD-L1 Checkpoint Inhibitors Market: Company Product Application Footprint
Table 50. PD-1/PD-L1 Checkpoint Inhibitors New Market Entrants and Barriers to Market Entry
Table 51. PD-1/PD-L1 Checkpoint Inhibitors Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 53. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2021-2026) & (K Units)
Table 54. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2027-2032) & (K Units)
Table 55. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2026) & (USD Million)
Table 56. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2027-2032) & (USD Million)
Table 57. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Region (2021-2026) & (US$/Unit)
Table 58. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Region (2027-2032) & (US$/Unit)
Table 59. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2026) & (K Units)
Table 60. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2027-2032) & (K Units)
Table 61. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type (2021-2026) & (USD Million)
Table 62. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Type (2027-2032) & (USD Million)
Table 63. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Type (2021-2026) & (US$/Unit)
Table 64. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Type (2027-2032) & (US$/Unit)
Table 65. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2026) & (K Units)
Table 66. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2027-2032) & (K Units)
Table 67. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application (2021-2026) & (USD Million)
Table 68. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application (2027-2032) & (USD Million)
Table 69. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Application (2021-2026) & (US$/Unit)
Table 70. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Application (2027-2032) & (US$/Unit)
Table 71. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2026) & (K Units)
Table 72. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2027-2032) & (K Units)
Table 73. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2026) & (K Units)
Table 74. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2027-2032) & (K Units)
Table 75. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2026) & (K Units)
Table 76. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2027-2032) & (K Units)
Table 77. North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2026) & (USD Million)
Table 78. North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2027-2032) & (USD Million)
Table 79. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2026) & (K Units)
Table 80. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2027-2032) & (K Units)
Table 81. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2026) & (K Units)
Table 82. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2027-2032) & (K Units)
Table 83. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2026) & (K Units)
Table 84. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2027-2032) & (K Units)
Table 85. Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2026) & (USD Million)
Table 86. Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2027-2032) & (USD Million)
Table 87. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2026) & (K Units)
Table 88. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2027-2032) & (K Units)
Table 89. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2026) & (K Units)
Table 90. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2027-2032) & (K Units)
Table 91. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2021-2026) & (K Units)
Table 92. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Region (2027-2032) & (K Units)
Table 93. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2021-2026) & (USD Million)
Table 94. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Region (2027-2032) & (USD Million)
Table 95. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2026) & (K Units)
Table 96. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2027-2032) & (K Units)
Table 97. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2026) & (K Units)
Table 98. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2027-2032) & (K Units)
Table 99. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2026) & (K Units)
Table 100. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2027-2032) & (K Units)
Table 101. South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2026) & (USD Million)
Table 102. South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2027-2032) & (USD Million)
Table 103. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2021-2026) & (K Units)
Table 104. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Type (2027-2032) & (K Units)
Table 105. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2021-2026) & (K Units)
Table 106. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Application (2027-2032) & (K Units)
Table 107. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2021-2026) & (K Units)
Table 108. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity by Country (2027-2032) & (K Units)
Table 109. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2021-2026) & (USD Million)
Table 110. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Country (2027-2032) & (USD Million)
Table 111. PD-1/PD-L1 Checkpoint Inhibitors Raw Material
Table 112. Key Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors Raw Materials
Table 113. PD-1/PD-L1 Checkpoint Inhibitors Typical Distributors
Table 114. PD-1/PD-L1 Checkpoint Inhibitors Typical Customers
List of Figures
Figure 1. PD-1/PD-L1 Checkpoint Inhibitors Picture
Figure 2. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type in 2025
Figure 4. PD-1 Inhibitors Examples
Figure 5. PD-L1 Inhibitors Examples
Figure 6. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application in 2025
Figure 8. Squamous Cell Skin Cancer Examples
Figure 9. Non-small Cell Lung Cancer Examples
Figure 10. Melanoma Examples
Figure 11. Gastric Cancer Examples
Figure 12. Other Examples
Figure 13. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 14. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 15. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity (2021-2032) & (K Units)
Figure 16. Global PD-1/PD-L1 Checkpoint Inhibitors Price (2021-2032) & (US$/Unit)
Figure 17. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Manufacturer in 2025
Figure 18. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Manufacturer in 2025
Figure 19. Producer Shipments of PD-1/PD-L1 Checkpoint Inhibitors by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 20. Top 3 PD-1/PD-L1 Checkpoint Inhibitors Manufacturer (Revenue) Market Share in 2025
Figure 21. Top 6 PD-1/PD-L1 Checkpoint Inhibitors Manufacturer (Revenue) Market Share in 2025
Figure 22. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Region (2021-2032)
Figure 23. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Region (2021-2032)
Figure 24. North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 25. Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 26. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 27. South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 28. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 29. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Type (2021-2032)
Figure 30. Global PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Type (2021-2032)
Figure 31. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Type (2021-2032) & (US$/Unit)
Figure 32. Global PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Application (2021-2032)
Figure 33. Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2021-2032)
Figure 34. Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Application (2021-2032) & (US$/Unit)
Figure 35. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Type (2021-2032)
Figure 36. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Application (2021-2032)
Figure 37. North America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Country (2021-2032)
Figure 38. North America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Country (2021-2032)
Figure 39. United States PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 40. Canada PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 41. Mexico PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 42. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Type (2021-2032)
Figure 43. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Application (2021-2032)
Figure 44. Europe PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Country (2021-2032)
Figure 45. Europe PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Country (2021-2032)
Figure 46. Germany PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 47. France PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 48. United Kingdom PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 49. Russia PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 50. Italy PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 51. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Type (2021-2032)
Figure 52. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Application (2021-2032)
Figure 53. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Region (2021-2032)
Figure 54. Asia-Pacific PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Region (2021-2032)
Figure 55. China PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 56. Japan PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 57. South Korea PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 58. India PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 59. Southeast Asia PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 60. Australia PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 61. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Type (2021-2032)
Figure 62. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Application (2021-2032)
Figure 63. South America PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Country (2021-2032)
Figure 64. South America PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Country (2021-2032)
Figure 65. Brazil PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 66. Argentina PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 67. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Type (2021-2032)
Figure 68. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Application (2021-2032)
Figure 69. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Sales Quantity Market Share by Country (2021-2032)
Figure 70. Middle East & Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value Market Share by Country (2021-2032)
Figure 71. Turkey PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 72. Egypt PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 73. Saudi Arabia PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 74. South Africa PD-1/PD-L1 Checkpoint Inhibitors Consumption Value (2021-2032) & (USD Million)
Figure 75. PD-1/PD-L1 Checkpoint Inhibitors Market Drivers
Figure 76. PD-1/PD-L1 Checkpoint Inhibitors Market Restraints
Figure 77. PD-1/PD-L1 Checkpoint Inhibitors Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of PD-1/PD-L1 Checkpoint Inhibitors in 2025
Figure 80. Manufacturing Process Analysis of PD-1/PD-L1 Checkpoint Inhibitors
Figure 81. PD-1/PD-L1 Checkpoint Inhibitors Industrial Chain
Figure 82. Sales Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Global Info Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們